Larimar Therapeutics Inc: Initial Takeaways from OL Data & Regulatory Updates for Nomla in FA

Research evidence excerpt

Larimar Therapeutics Inc: Initial Takeaways from OL Data & Regulatory Updates for Nomla in FA

J P M O R G A N North America Equity Research

29 June 2026

Larimar Therapeutics Inc Overweight

LRMR, LRMR US

Initial Takeaways from OL Data & Regulatory Updates Price (26 Jun 26):$3.66

for Nomla in FA

SMid Biotechnology

Earlier this morning, Larimar reported additional data from its open label (OL) study Tessa T Romero AC

evaluating nomlabofusp (nomla) in Friedreich's ataxia (FA) and provided a regulatory (1-212) 622-4484

update. At a high level, we were encouraged by the increased and sustained tessa.t.romero@jpmchase.com

improvements in skin frataxin (FXN) levels at 1yr and 18mo and continued Caroline Pocher

directional improvements across other clinical outcomes (mFARS, FARS-ADL, 9- (1-212) 622-8204

HPT and MFIS) at 1yr relative to a worsening in a FACOMS natural history study caroline.pocher@jpmchase.com

reference population. More specifically, on the safety profile, which has been a key Mariam Waggeh

focus for investors, we were not surprised by the three additional cases of anaphylaxis (1-212) 622-1711

mariam.waggeh@jpmchase.com

that, again, have been manageable and responsive to treatment, given there seems to J.P. Morgan Securities LLC

be a heightened risk following a gap in exposure to nomla (indicating greater than a

~3-4mo gap; see our initiation note here for more details). Further, we think the

discontinuation rate (n=21 patients discontinued) needs to be put into the context,

given that most of these discontinuations (n=13/21) were driven by anaphylaxis and

generalized urticaria events, mostly in patients who had prior exposure to the drug (1

patient did not have prior exposure), and thus we would expect this rate to come down